Naturally Occurring Mutations within 39 Amino Acids in the Envelope Glycoprotein of Maedi-Visna Virus Alter the Neutralization Phenotype

ABSTRACT Infectious molecular clones have been isolated from two maedi-visna virus (MVV) strains, one of which (KV1772kv72/67) is an antigenic escape mutant of the other (LV1-1KS1). To map the type-specific neutralization epitope, we constructed viruses containing chimeric envelope genes by using KV1772kv72/67 as a backbone and replacing various parts of the envelope gene with equivalent sequences from LV1-1KS1. The neutralization phenotype was found to map to a region in the envelope gene containing two deletions and four amino acid changes within 39 amino acids (positions 559 to 597 of Env). Serum obtained from a lamb infected with a chimeric virus, VR1, containing only the 39 amino acids from LV1-1KS1 in the KV1772kv72/67 backbone neutralized LV1-1KS1 but not KV1772kv72/67. The region in the envelope gene that we had thus shown to be involved in escape from neutralization was cloned into pGEX-3X expression vectors, and the resulting fusion peptides from both molecular clones were tested in immunoblots for reactivity with the KV1772kv72/67 and VR1 type-specific antisera. The type-specific KV1772kv72/67 antiserum reacted only with the fusion peptide from KV1772kv72/67 and not with that from LV1-1KS1, and the type-specific VR1 antiserum reacted only with the fusion peptide from LV1-1KS1 and not with that from KV1772kv72/67. Pepscan analysis showed that the region contained two linear epitopes, one of which was specific to each of the molecularly cloned viruses. This linear epitope was not bound by all type-specific neutralizing antisera, however, which indicates that it is not by itself the neutralization epitope but may be a part of it. These findings show that mutations within amino acids 559 to 597 in the envelope gene of MVV virus result in escape from neutralization. Furthermore, the region contains one or more parts of a discontinuous neutralization epitope.

[1]  B. Meyer,et al.  The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain , 1997, Journal of virology.

[2]  V. Andrésdóttir,et al.  In vivo and in vitro infection with two different molecular clones of visna virus. , 1997, Virology.

[3]  O. Narayan,et al.  Plasmas from lymphocyte- and macrophage-tropic SIVmac-infected macaques have antibodies with a broader spectrum of virus neutralization activity in macrophage versus lymphocyte cultures. , 1997, Virology.

[4]  J. Clements,et al.  Antigenic variation of SIV: mutations in V4 alter the neutralization profile. , 1996, Virology.

[5]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[6]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[7]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[8]  F. Guiguen,et al.  Replication properties of dUTPase-deficient mutants of caprine and ovine lentiviruses , 1996, Journal of virology.

[9]  A. Osterhaus,et al.  Neutralization of feline immunodeficiency virus by polyclonal feline antibody: simultaneous involvement of hypervariable regions 4 and 5 of the surface glycoprotein , 1995, Journal of virology.

[10]  Marian C. Horzinek,et al.  A single mutation within the V3 envelope neutralization domain of feline immunodeficiency virus determines its tropism for CRFK cells , 1995, Journal of virology.

[11]  R. Weiss,et al.  Change in tropism upon immune escape by human immunodeficiency virus , 1995, Journal of virology.

[12]  R. F. Cook,et al.  Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein , 1995, Journal of virology.

[13]  R. Desrosiers,et al.  Effects of natural sequence variation on recognition by monoclonal antibodies neutralize simian immunodeficiency virus infectivity , 1994, Journal of virology.

[14]  M. Bendinelli,et al.  Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system , 1994, Journal of virology.

[15]  L. Sawyer,et al.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated , 1994, Journal of virology.

[16]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[17]  M. Reitz,et al.  Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. , 1993, The Journal of biological chemistry.

[18]  A. Osterhaus,et al.  A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization , 1993, Journal of virology.

[19]  J. D. Greenwood,et al.  Nucleotide sequence and biological properties of a pathogenic proviral molecular clone of neurovirulent visna virus. , 1993, Virology.

[20]  J. Moore,et al.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans , 1993, Journal of virology.

[21]  R. Desrosiers,et al.  The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Kuiken,et al.  Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. , 1991, Virology.

[23]  R. Dalziel,et al.  Nucleotide sequence of EV1, a British isolate of maedi-visna virus. , 1991, The Journal of general virology.

[24]  A. Haase,et al.  Isolation of replication-competent molecular clones of visna virus. , 1991, Virology.

[25]  J. Clements,et al.  Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus. , 1990, Virology.

[26]  R. Gallo,et al.  Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees , 1990, Journal of virology.

[27]  G. Quérat,et al.  Nucleotide sequence analysis of SA-OMVV, a visna-related ovine lentivirus: phylogenetic history of lentiviruses. , 1990, Virology.

[28]  J. Albert,et al.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.

[29]  L. Pearl,et al.  Characterization of HIV‐1 neutralization escape mutants , 1989, AIDS.

[30]  L. Arthur,et al.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A J Langlois,et al.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Braun,et al.  The visna virus genome: evidence for a hypervariable site in the env gene and sequence homology among lentivirus envelope proteins , 1987, Journal of virology.

[33]  G. Nakamura,et al.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor , 1987, Cell.

[34]  H. Gendelman,et al.  Tropism of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages , 1986, Journal of virology.

[35]  A. Haase,et al.  Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus , 1985, Cell.

[36]  H. M. Geysen,et al.  Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[37]  H. Thormar,et al.  The emergence of antigenic variants is a rare event in long-term visna virus infection in vivo. , 1983, The Journal of general virology.

[38]  G. Georgsson,et al.  Antigenic drift in visna: virus variation during long-term infection of Icelandic sheep. , 1983, The Journal of general virology.

[39]  J. Clements,et al.  Slow virus replication: the role of macrophages in the persistence and expression of visna viruses of sheep and goats. , 1982, The Journal of general virology.

[40]  D. Griffin,et al.  Antigenic shift of visna virus in persistently infected sheep. , 1977, Science.

[41]  H. Panitch,et al.  Pathogenesis of visna. I. Sequential virologic, serologic, and pathologic studies. , 1976, Laboratory investigation; a journal of technical methods and pathology.

[42]  B. Sigurdsson,et al.  Visna of sheep; a slow, demyelinating infection. , 1958, British journal of experimental pathology.

[43]  B SIGURDSSON,et al.  Maedi, a chronic, progressive infection of sheep's lungs. , 1952, The Journal of infectious diseases.

[44]  M. Sitbon,et al.  Conserved framework of envelope glycoproteins among lentiviruses. , 1994, Current topics in microbiology and immunology.

[45]  G. Georgsson Maedi - Visna. Pathology and Pathogenesis , 1990 .

[46]  G. Pétursson,et al.  Maedi-Visna and Related Diseases , 1990, Developments in Veterinary Virology.

[47]  C. Boucher,et al.  Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. , 1988, AIDS.

[48]  G. Georgsson,et al.  Pathogenesis of Visna , 1987 .

[49]  M. Gudnadóttir Visna-maedi in sheep. , 1974, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale.